NEW YORK (GenomeWeb) – Episona announced today that it has raised approximately $4 million in seed financing to support the expansion of its first commercial product, Seed — an epigenetic test for male infertility and embryo quality.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.